Dr Michael Berendt
Guest ContributorNovember 11, 2013
Dr Michael Berendt has been appointed CEO of Bioniche Life Sciences Inc, effective immediately, replacing company founder and CEO Graeme McRae, who is retiring but retains the title of chairman emeritus of the board of directors (R$, September 26/13). Berendt was recently president and CEO of Montreal-based Aegera Therapeutics Inc. until it was sold to Pharmascience in 2011. He is executive chairman of Anchor Therapeutics and chairman of Alethia Biothérapeutics. Berendt holds a BSc from Ohio Dominican Univ, an MSc from Miami Univ and a PhD in medical microbiology and immunology from Drexel Univ....
Other News
Events For Leaders in
Science, Tech, Innovation, and Policy
Discuss and learn from those in the know at our virtual and in-person events.
See Upcoming Events
You have 1 free article remaining.
Don't miss out - start your free trial today.
Start your FREE trial Already a member? Log in
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.